… Nintedanib, an intracellular inhibitor of … nintedanib reduces the rate of decline in FVC (milliliters/year).
The objective of the current analyses was to investigate the effects of nintedanib on …

… In this manuscript, we characterise the effects of nintedanib across a number of univariate
and composite physiologic outcomes using pooled data from the INPULSIS ® trials. …

… Nintedanib slowed the decline in lung function independent of the degree of FVC impairment
at baseline, with a similar adverse event profile in both subgroups. These findings support …

… data from studies of nintedanib in malignancy, paved the … with nintedanib may potentially
slow decline in lung function, … preclinical data they suggest that nintedanib may yet become an …

… Nintedanib is an intracellular inhibitor of tyrosine kinases … lung function decline in patients
with ILD associated with systemic sclerosis (SSc-ILD). In vitro data demonstrate that nintedanib …

… with architectural distortion due to fibrosis using a support vector machine classifier and
has been shown to correlate with lung function measurements in patients with ILDs [15-23]. …

… Nintedanib resulted in a prominent improvement in … the effect of nintedanib on lung function
and inflammation. These findings uncover a potential new mode of action of nintedanib that …

… Our data confirmed that patients profit from therapy as lung function stabilization was observed
in nearly half of patients for at least 6 months. Nintedanib therapy was not associated with …

… nintedanib for treatment of post-COVID-19 pulmonary fibrosis. This study aimed to determine
the effects of nintedanib in patients with COVID-19 lung … decline in lung function, reduced …

… of decline in FVC between the nintedanib and placebo groups was … nintedanib 150 mg
twice daily slowed the decline in lung function in patients with IPF, independent of severity of lung …